BCAL Diagnostics (ASX:BDX) EBITDA Margin %: -7,900.00% (As of Dec. 2025)


What is BCAL Diagnostics EBITDA Margin %?

BCAL Diagnostics ASX:BDX +10.96% EBITDA Margin % is -7,900.00% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 98.53% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BCAL Diagnostics's EBITDA for the six months ended in Dec. 2025 was A$-3.40 Mil. BCAL Diagnostics's Revenue for the six months ended in Dec. 2025 was A$0.04 Mil. Therefore, BCAL Diagnostics's EBITDA margin for the quarter that ended in Dec. 2025 was -7,900.00%.

BCAL Diagnostics  (ASX:BDX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

BCAL Diagnostics EBITDA Margin % Related Terms

BCAL Diagnostics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics EBITDA Margin % Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
0.00 0.00 0.00 -28,150.00

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -7,900.00

ASX:BDX vs TMO, DHR, IDXX: EBITDA Margin % Comparison

For the Diagnostics & Research subindustry, BCAL Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics EBITDA Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's EBITDA Margin % falls into.


BCAL Diagnostics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BCAL Diagnostics's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-6.193/0.022
=-28,150.00 %

BCAL Diagnostics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.397/0.043
=-7,900.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -7,900.00% mean?
BCAL Diagnostics (ASX:BDX) has a EBITDA Margin % of -7,900.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #201 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 98.5%.
Is BCAL Diagnostics' EBITDA Margin % too high?
BCAL Diagnostics' current EBITDA Margin % is -7,900.00%. Based on the distribution chart, BCAL Diagnostics ranks #201 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does BCAL Diagnostics' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #201 out of 204 companies for EBITDA Margin %. This places BCAL Diagnostics in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current EBITDA Margin % is -7,900.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current EBITDA Margin % of -7,900.00%. The current EBITDA Margin % is -7,900.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current EBITDA Margin % is -7,900.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.